Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afimkibart induction therapy study in moderately to severely active ulcerative colitis
NL-OMON59776Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Afimkibart with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12. Started Mar 2025; status: active, not recruiting.
02
Drugs
afimkibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON59776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59776.